Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acceleron Pharma, US based discoverer, developer and manufacturer of novel protein therapeutics for orphan diseases and cancer, has started a dose-escalating, multiple-dose Phase 1 to evaluate ACE-536.
Subscribe to our email newsletter
ACE-536 is being developed as a treatment of anemia in a global collaboration with Celgene Corporation.
The trial aims to evaluate the tolerability, pharmacodynamics, safety and pharmacokinetics of ACE-536.
Acceleron will receive a $7.5m payment from Celgene for achieving this milestone event.
Acceleron CEO John Knopf said ACE-536 has the potential to make a significant impact on the treatment of anemia, specifically, in diseases such as Myelodysplastic syndromes and beta-thalassemia in which the severe anemia isn’t well managed by currently available therapies.
"ACE-536 is our fourth internally discovered, developed and manufactured drug to enter human clinical trials in the past five years," Knopf said.